These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 17169036)

  • 1. The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line.
    Mazza F; Tronconi E; Valerio A; Groettrup M; Kremer M; Tossi A; Benedetti F; Cargnel A; Atzori C
    J Eukaryot Microbiol; 2006; 53 Suppl 1():S144-6. PubMed ID: 17169036
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.
    Tronconi E; Mazza F; Valerio A; Rinaudo MT; Piccinini M; Anselmino A; Cargnel A; Atzori C
    J Eukaryot Microbiol; 2006; 53 Suppl 1():S142-3. PubMed ID: 17169035
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.
    Atzori C; Villani P; Regazzi M; Mazza F; Valerio A; Tronconi E; Maruzzi M; Cargnel A
    J Eukaryot Microbiol; 2006; 53 Suppl 1():S140-1. PubMed ID: 17169034
    [No Abstract]   [Full Text] [Related]  

  • 4. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
    Doyon L; Tremblay S; Bourgon L; Wardrop E; Cordingley MG
    Antiviral Res; 2005 Oct; 68(1):27-35. PubMed ID: 16122817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.
    Gallego O; de Mendoza C; Corral A; Barrios A; Soriano V
    AIDS Patient Care STDS; 2005 Feb; 19(2):67-9. PubMed ID: 15716637
    [No Abstract]   [Full Text] [Related]  

  • 6. New resistance score for tipranavir.
    Poveda E
    AIDS Rev; 2008; 10(2):127. PubMed ID: 18615125
    [No Abstract]   [Full Text] [Related]  

  • 7. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
    Baxter JD; Schapiro JM; Boucher CA; Kohlbrenner VM; Hall DB; Scherer JR; Mayers DL
    J Virol; 2006 Nov; 80(21):10794-801. PubMed ID: 16928764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.
    Back NK; van Wijk A; Remmerswaal D; van Monfort M; Nijhuis M; Schuurman R; Boucher CA
    AIDS; 2000 Jan; 14(1):101-2. PubMed ID: 10714580
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.
    Vourvahis M; Kashuba AD
    Pharmacotherapy; 2007 Jun; 27(6):888-909. PubMed ID: 17542771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
    Bulgheroni E; Citterio P; Croce F; Lo Cicero M; Viganò O; Soster F; Chou TC; Galli M; Rusconi S
    J Antimicrob Chemother; 2004 Mar; 53(3):464-8. PubMed ID: 14963061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
    Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
    Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms.
    Champenois K; Bocket L; Deuffic-Burban S; Cotte L; André P; Choisy P; Yazdanpanah Y
    AIDS; 2008 May; 22(9):1087-9. PubMed ID: 18520355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
    Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S
    J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New PI active against many strains.
    AIDS Patient Care STDS; 1999 Sep; 13(9):568. PubMed ID: 10813041
    [No Abstract]   [Full Text] [Related]  

  • 18. Tipranavir.
    Flexner C; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Dec; 4(12):955-6. PubMed ID: 16370086
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection of rat Pneumocystis carinii proteinases and elastase and antipneumocystis activity of proteinase inhibitors in vitro.
    Atzori C; Mainini A; Agostoni F; Angeli E; Bartlett M; Bruno A; Scaglia M; Cargnel A
    Parasite; 1999 Mar; 6(1):9-16. PubMed ID: 10229932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.
    Graff J; von Hentig N; Kuczka K; Angioni C; Gute P; Klauke S; Babacan E; Harder S
    J Antimicrob Chemother; 2008 Feb; 61(2):394-9. PubMed ID: 18156609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.